ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Core Insights - ALX Oncology is advancing its clinical pipeline, focusing on the CD47-blocker evorpacept and the novel EGFR-directed ADC candidate ALX2004, with key updates provided during an R&D Day webcast event [1][8] Clinical Development Updates - The company is enhancing its evorpacept program, particularly in combination with existing anti-cancer therapies for HER2-positive cancers, with new trials planned for breast and colorectal cancers expected to start in the first half of 2025 [3][4] - ALX2004, a new ADC candidate, is set for an Investigational New Drug (IND) submission to the FDA in Q1 2025, aiming to optimize anti-tumor activity [6][8] Corporate Strategy and Financial Updates - ALX Oncology is implementing strategic prioritization and resource optimization, resulting in a workforce reduction of approximately 30% in preclinical research to extend its cash runway into Q4 2026 [9][8] - The company is focusing resources on high-priority programs to ensure successful execution of ongoing studies and to generate value from its cancer therapies [3][9]